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Introduction
Squamous cell carcinoma of the larynx is currently the
second most common malignancy of the airway after lung
cancer,1 and hypopharyngeal cancer accounts for fewer than
5% of head and neck cancers.2 Different treatment options
exist, and they can be surgical or nonsurgical, such as radio-
therapy (RT) or chemoradiotherapy (CRT).
In advanced stages of the disease, the treatment strategy
has evolved to combine functional preservation (speech,
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Abstract Introduction Squamous cell carcinoma of the larynx is currently the second most
common malignancy of the airway after lung cancer, and hypopharyngeal cancer
accounts for fewer than 5% of head and neck cancers. The nonsurgical options for
patients with this disease are related to significant long-term toxicities and the need for
persistent tracheostomy, which adversely affects the quality of life of these patients.
Objective To evaluate the need for tracheostomy, and the influence of this in the
overall and specific survival rates of patients diagnosed with all stages of laryngeal
carcinoma treated by chemoradiotherapy.
Methods A retrospective study of patients diagnosed with laryngeal carcinoma was
performed according to the criteria of the Union for International Cancer Control
(UICC) and the American Joint Committee on Cancer (AJCC) 7th edition, in a tertiary
hospital.
Results A total of 21 patients were evaluated, 8 patients required a tracheotomy
(31%) during the treatment protocol, 7 (35%) men and 1 (100%) women. According to
subsite 4/4 patient with glottis cancer (p  0.001), 2/10 patients with supra glottis
cancer and 2/7 patients with hypopharyngeal cancer. During follow up, just in 1 patient
was possible to close the tracheostomy.
Conclusion Persistent tracheostomy dependence after primary chemoradiation in-
creases significantly the morbidity, and decreases the quality of life of those patients.
Patients with glottis cancer are prone to need a tracheostomy, but no statistical
difference regarding the oncological stage and the need for a tracheostomy were
detected. Amore thorough selection of the patients is needed to improve the quality of
life and reduce permanent tracheostomy dependence.
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swallowing, and respiration) and loco-regional control to
increase survival rates. Despite this, laryngeal cancer re-
mains today as the only tumor for which life expectancy
has declined in recent decades, and this is thought to be due
to the organ preservation protocols.3,4 The prognosis of
hypopharyngeal cancer continues to be worse than that of
other types of cancer due to its late presentation, with 70–
90% of patients having stage III or IV diseases at the time of
presentation, and this is at least in part attributable to the
anatomy, the rapid lymphatic spread of these tumors and the
location of the hypopharynx.5
Although chemoradiation protocols can achieve loco-re-
gional control,6,7many of the patients experience significant
long-term toxicities,8,9 and their quality of life is adversely
affected. Speech and swallowing dysfunctions are the most
commonly reported complications after the organ preserva-
tion protocols. However, the need for persistent tracheost-
omy also represents a treatment complication, due to the
financial, speech, and swallowing implications, which ad-
versely affect the quality of life of these patients.10
For this reason, the aim of this study is to retrospectively
evaluate the rate of persistent tracheostomy in a series of
patients treated by CRT for all stages of laryngeal carcinomas
in a tertiary university hospital.
Material and Methods
A retrospective analysis of those patients diagnosed with a
laryngeal carcinoma (T1, T2, T3, T4), N -/þ, M -/þ, was
performed according to the criteria of the Union for Inter-
national Cancer Control (UICC) and the American Joint
Committee on Cancer (AJCC) 7th edition, in a tertiary hospi-
tal. Patients treated with radiotherapy or radiotherapy þ
chemotherapy between January 2009 and March 2012 were
included. The identification of the cases was achieved by a
search in the medical records of our department using the
codes from the International Classification of Diseases (ICD)-
10. No approval from the ethics committee of our institution
was needed, due the retrospective nature of our study.
Demographic data (age, gender), medical history, onco-
logical stage, information on diagnostic tests, histological
findings and complications were obtained through a review
of the medical records.
Radiation therapy was performed according to the proto-
cols established in our hospitals with intensity modulated
radiation therapy (IMRT). The dose used was 70 to 72 Gray
(Gy) over the primary site and clinically positive neck dis-
ease, and 50 Gy for clinically negative cervical lymph node to
approach the risk of regional metastasis. Chemotherapy
regimens were platinum-based and delivered weekly during
the radiation therapy to standard area-under-the-curve
dosing.
Before the treatment, all cases were discussed by the
members of an interdisciplinary committee of head and
neck tumors. Patients with suspicion of malignant lesions
were scheduled for laryngeal microsurgery with biopsy.
After this, the best treatment option according to the exten-
sion of the disease and the comorbiditieswasproposed to the
patient, and both clinician and patient decided on the best
option to treat the disease.
In our service, patients treated for head and neck malig-
nant tumors are followed-up for at least 5 years at the
Department of Head and Neck Oncology. However, for this
study, we considered a group of patients that had been
followed-up for a minimum of 36 months.
Statistical analysis was performed using the Statistical
Package for the Social Sciences software for Windows, ver-
sion 20.0 (IBM SPSS, Chicago, Il, US). The quantitative vari-
ables in the study were expressed as mean  standard
deviation (SD). The differences between the groups were
studied using the chi-square test, while the correlations
between the variables were analyzed using the Spearman’s
rank correlation coefficient. We calculated the overall survi-
val and the specific survival rates using the Kaplan-Meier
survival analysis. As reference for the overall survival, we
used the survival time from the surgery until the last follow-
up visit or date of death, regardless of cause. For the specific
survival, we considered the time between the surgery until
death caused by the tumor, or until a total laryngectomywas
performed. We calculated the influence of various factors on
survival using the log-rank method.
Results
Total 21 patients were evaluated, 20 (95.2%) men and 1
woman (4.8%). The average age was 60.9 years ( 9.89 ¼
Min. 45/Max. 83). A total of 18 patients (85.7%) consumed
> 70 g of alcohol per day. All of them (100%) were smokers
who consumed more than 40 packs per year. Six patients
(28.5%) were diabetic, and 14 (66.7%) hypertensive. The
mean follow-up was 36 months ( 29.2 ¼ Min: 6/Max:
36). Regarding the oncological stage, 14 patients (66.6%)
were on cT3, and 7 (33.3%) were on cT4. A total of 8 patients
(38.1%) were classified as N0; 1 (4.8%) as N1; 10 (47.61%) as
N2; and 2 (9.5%) as N3. There were 2 (9.5%) cases of distant
metastases.
Among all patients, 8 (31%) required a tracheotomy dur-
ing the treatment protocol, 7 (35%) men and 1 (100%)
woman. Regarding the subsite, 4 out of 4 patients with
glottis cancer (p  0.001), 2 out of 10 patients with supra-
glottis cancer, and 2 out of 7 patients with hypopharyngeal
cancer required tracheostomies. The overall rate of tra-
cheostomy before the primary organ preservation protocol
was of 23.8% (5 patients) due to dyspnea before starting the
treatment, and another 3 patients (14.2%) received new
tracheostomies for airway compromise in thefirst 12months
after the primary chemoradiation (p ¼ 0.162) due to laryn-
geal edema and dyspnea. According to the oncological stage,
4 out of 14 patients with T3 stage diseases and 4 out of 7
patients with T4 stage diseases received a tracheostomy
(p ¼ 0.648) during all of the follow-up. Among the 5 patients
who required tracheostomies before receiving chemoradia-
tion, 2 had T3 stage tumors, and the tumoral subsite affected
was the glottis for one patient and the supraglottis for the
other; and 3 patients had T4 stage tumors, and the affected
subsite was different for each one of them (glottis,
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supraglottis and hypopharynx) (p ¼ 0.269). During the fol-
low-up, we could only remove and close the tracheostomy of
one patient (►Fig. 1). Data according to tumoral subsite, T
stage and need for tracheostomy before or during the organ
preservation protocol can be seen on ►Table 1.
Regarding survival, in the group of patients who needed
a tracheotomy during the treatment, the 3-year overall
survival rate was 25%, while the 3-year disease-specific
survival rate was 12.5%. In the group of patients who did
not need a tracheostomy, the 3-year overall survival rate
was 38.5%, and the 3-year disease-specific survival rate was
15.4%. There were no statistically significant differences
between both arms according to the overall (p ¼ 0.551)
or specific survival rates (p ¼ 0.779) (►Figs. 2–3). During
the follow-up, 3 patients (14.2%) with tumors affecting the
glottis needed a total laryngectomy performed to achieve
local control. Out of these patients, two were in the no
tracheostomy group, and one was in the no tracheostomy
group.
Discussion
During the past 30 years, the therapeutic options for patients
with laryngeal cancer have changed. However, the best
approach is still a controversial issue, and many accepted
surgical and non-surgical oncological treatments have been
currently established.
In the past, the treatment of advanced tumors included
surgery with or without radiotherapy according to nodal
involvement and resection margins as the main therapeutic
option. Nowadays, non-advanced carcinomas and selected
advanced-stage tumors are managed with conservative sur-
gery, such as open partial laryngectomy, transoral CO2 laser
microsurgery (TLM), transoral robotic surgery (TORS), plus
radiotherapy or chemoradiotherapy.11 However, in advanced
tumors, if laryngeal preservation is themain goal, the patients
are treated with concurrent CRT.12 Although this regimen has
demonstrated efficacy in preserving the larynx, several of the
patients submitted to it have ultimately required salvage
laryngectomy13 or suffer from present long-term sequelae.
The Veterans Affairs Laryngeal Cancer Study Group14
findings published in 1991 heralded a shift in emphasis
toward organ preservation via CRT for treatment of advanced
laryngeal cancer. Moreover, the long-term results of the
Radiation Therapy Oncology Group (RTOG) 91–11 trial
show that concomitant CRT obtains better local control
and a higher laryngeal preservation rate than radiotherapy
alone or preceded by induction chemotherapy.15
21 paents  
13 did not require 
a tracheostomy
8 required a 
tracheostomy
Aer 12 months, 
only 1 paent was 
decannulated
3 paents during 
the CRT 
5 paents before 
the beginning of 
the CRT
Fig. 1 Patients included in the study according the need for tracheostomy. Abbreviation: CRT, chemoradiotherapy.
Table 1 Data according to tumoral subsite, T stage and need for tracheostomy before the treatment or during the organ
preservation protocol
Tumoral Site Tumoral
stage
Pre-treatment
tracheostomy
Treatment
tracheostomy
No
tracheostomy
Total
subsite %
Supraglottis T3
T4
1
1
0
0
7
1
47.61
Glottis T3
T4
1
1
1
1
0
0
19.04
Hypopharynx T3
T4
0
1
1
0
3
2
33.3
Total 5 3 13 21 (100)
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However, the use of nonsurgical techniques as the pri-
mary therapy for advanced larynxcancer has been associated
with reductions in survival. Hoffman et al reported a 3.4%
drop in 5-year survival rates in 1994–1996 versus 1985–
1990 in a National Cancer Database outcomes study.3
Despite this, the need for tracheostomy is acknowledged
as an adverse prognostic factor. Larynx-preserving strategies
are still being utilized in this population because of the
confirmation of survival equivalence16 and the powerful
desire of the patients to preserve their voices.17
In a study performed by Stanton et al, severe laryngophar-
yngeal dysfunction, defined as a persistent need for gastro-
stomy or tracheostomy, was present in 36% of the patients
who underwent organ preservation treatments for advanced
laryngeal malignancies and remained disease-free at
6 months after the completion of the therapy protocols.18
But, as we know, persistent tracheostomy requirement is
also associated with poor functional outcome, requiring
salvage surgery in many cases.13 Another study performed
by Hutcheson et al studied the outcomes of patients who
were rendered disease-free after an organ-sparing treatment
but subsequently underwent elective total laryngectomy,
and found that 39% of these individuals were tracheost-
omy-dependent before the removal of their larynges.19
In another study performed by Tennant et al, in patients
with stage III or IV laryngeal or hypopharyngeal squamous
cell carcinoma, 34% of them had tracheostomies performed
on the, before the initiation of the treatment. The majority of
the tracheostomies were performed for immediate or im-
pending airway compromise. Moreover, they included pa-
tients who presented with T1 or T2 diseases, and they found
that none of them were tracheostomy-dependent at the
12-month follow-up time interval.13
In our study, 5 (23.8%) patients had tracheostomies per-
formed before the initiation of the treatment, and another 3
(14.2%) patients had tracheostomies performed during the
treatment. After 12 months of treatment, 7 (33.3%) patients
were tracheostomy-dependent, a result similar to those
reported in the literature, and, as we expected, patients
with tumors involving the glottis were more likely to have
a tracheostomy (p  0.001) (►Fig. 1) performed on them.
However, we did not find differences regarding tumoral
stage, subsite and the need for tracheostomy (p ¼ 0.648).
Moreover, there were no statistically significant differences
between both arms according to the overall (p ¼ 0.748) and
specific survival rates (p ¼ 0.936).
However, our study has several limitations: primarily, it is
a retrospective analysis, and the small sample size may limit
the validity of our results. A short follow-up period (36
months) and the fact that no quality of life questionnaires
were administered to the patients also limit our study.
However, we only included those patients on advanced
oncological stages, and a worse prognosis can be expected
inmore advanced tumors. Therefore, we suggest the need for
prospective studies about the influence of permanent tra-
cheostomy in these patients, because in a new era in which
medical advances help to increase life expectancy, it is
important to know the functional outcomes according to
the different treatment options available.
Conclusion
Patients with glottis carcinoma and advanced oncological
disease of the larynx and hypopharynx can be more prone to
suffer hemilarynx fixation and require a pre-treatment
tracheostomy. Therefore, and according to previous reports,
these patients are poor candidates for organ preservation
treatments. Moreover, persistent tracheostomy dependence
after primary chemoradiation increases significantly the
morbidity, and decreases the quality of life of those patients.
Patients with glottis cancer are more prone to need a
tracheostomy, but no statistical difference according to the
Fig. 3 Kaplan-Meier three-year specific survival according the need
for tracheostomy.
Fig. 2 Kaplan-Meier three-year overall survival according the need for
tracheostomy.
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oncological stage and the need for tracheostomy were de-
tected. A more thorough patient selection is needed to
improve the quality of life of our patients and reduce the
permanent tracheostomy dependence.
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